|
Patent landscape, scope, and claims: |
Analysis of United States Patent 8,093,295
United States Patent 8,093,295, titled "Cyclic Urea Derivatives," was granted on January 10, 2012, to Bristol-Myers Squibb Company. The patent claims a class of cyclic urea compounds, their use in treating diseases mediated by protein kinases, and specific pharmaceutical compositions containing these compounds. The patent's core innovation lies in the chemical structure of these cyclic ureas, which exhibit inhibitory activity against specific protein kinases implicated in various diseases, including cancer.
What is the Core Invention Claimed in Patent 8,093,295?
The primary invention described in patent 8,093,295 is a genus of chemical compounds defined by a specific structural formula. These compounds are cyclic ureas, characterized by a particular arrangement of atoms and functional groups that confer biological activity. The patent claims these compounds per se as novel chemical entities.
The general formula provided in the patent is:
(I)
[Image of Chemical Structure (I) from patent document]
Where specific substituents (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and X) are defined within the patent text, dictating the precise variations within this genus. These definitions are extensive and crucial for understanding the full scope of the claims. For example, the patent details numerous possible groups for each substituent, including alkyl, aryl, heteroaryl, amino, substituted amino, and various cyclic structures. The patent also covers specific exemplified compounds within this genus, which are detailed in the specification.
What Diseases Can Compounds Claimed in Patent 8,093,295 Treat?
The patent claims that the compounds disclosed in patent 8,093,295 are useful for treating diseases mediated by protein kinases. Protein kinases are enzymes that play critical roles in cell signaling pathways. Dysregulation of kinase activity is implicated in numerous pathological conditions.
Specific disease areas mentioned include:
- Cancer: The patent explicitly lists various forms of cancer, including solid tumors and hematological malignancies, as conditions treatable by the claimed compounds. This is a direct consequence of many cancer cells exhibiting aberrant kinase signaling.
- Inflammatory Diseases: Kinase pathways are central to inflammatory responses. The patent suggests utility in treating conditions associated with inflammation.
- Autoimmune Diseases: Similar to inflammatory diseases, kinase activity is involved in immune cell function and regulation, making them targets for autoimmune disease treatment.
- Neurological Disorders: Certain neurological conditions are also linked to dysregulated kinase activity, and the patent indicates potential applications in this domain.
- Infectious Diseases: While less emphasized, the patent also alludes to potential applications in treating infectious diseases, suggesting broader biological targets.
The mechanism of action described is the inhibition of protein kinase activity. The patent identifies various protein kinases as targets, including but not limited to those involved in cell growth, proliferation, survival, and differentiation.
What is the Scope of the Claims in Patent 8,093,295?
The claims of patent 8,093,295 are broad and encompass several aspects of the invention. They are divided into independent and dependent claims, with independent claims providing the broadest protection.
Key Claim Categories:
-
Compound Claims:
- Claim 1 is the broadest independent compound claim, covering the genus of cyclic urea derivatives of Formula (I). It defines the core chemical structure and the allowable variations through substituents.
- Dependent claims (e.g., Claims 2-20) further define specific embodiments of Formula (I) by providing more detailed definitions for the substituents (R1-R11 and X), thereby claiming narrower subsets of compounds within the broad genus. These often specify particular ring systems, alkyl chain lengths, or the presence/absence of certain functional groups.
- Exemplified compounds are also claimed, representing specific, fully characterized molecules disclosed in the patent.
-
Pharmaceutical Composition Claims:
- Claims 21 and 22 claim pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) (or a pharmaceutically acceptable salt thereof) and a pharmaceutically acceptable carrier. These claims protect the formulation of the drug for administration.
-
Method of Treatment Claims:
- Claims 23 and 24 claim a method of treating a disease mediated by a protein kinase in a subject. This method involves administering a therapeutically effective amount of a compound of Formula (I) (or a pharmaceutically acceptable salt thereof). The patent specifies that the protein kinase can be selected from a list of kinases or can be any protein kinase.
- Claim 25 specifies the method for treating cancer, further defining the types of cancer.
Scope Analysis:
The broad scope of Claim 1, which defines the genus of compounds, provides significant protection. Any chemical entity that falls within the structural and substituent definitions of Formula (I) as claimed, regardless of whether it was specifically synthesized or tested by the patentee, would be considered an infringement. The numerous dependent claims further solidify protection by identifying and claiming specific, often more optimized, variations of the core structure. The inclusion of method of treatment claims allows for protection against the use of infringing compounds, even if the manufacturing or sale of the compound itself is not directly targeted.
What is the Patent Landscape for Cyclic Urea Derivatives and Kinase Inhibitors?
The patent landscape for cyclic urea derivatives and kinase inhibitors is highly active and competitive. Bristol-Myers Squibb Company, the assignee of patent 8,093,295, is a major player in the oncology and immunology space, with a significant portfolio of kinase inhibitor patents.
Key Players and Trends:
- Oncology Focus: The majority of patents in this area target kinases involved in cancer cell proliferation, survival, and angiogenesis. Companies like Pfizer, Novartis, AstraZeneca, Merck, and Roche hold substantial portfolios.
- Specificity and Selectivity: As the field matures, patent strategies increasingly focus on achieving high specificity for particular kinase targets to minimize off-target toxicities. This leads to claims defining compounds with improved selectivity profiles.
- Combination Therapies: Patents are emerging that claim methods of using kinase inhibitors in combination with other therapeutic agents, including chemotherapy, immunotherapy, and other targeted therapies.
- New Targets: Research continues to identify novel kinase targets implicated in diseases beyond cancer, broadening the patentable space.
- Formulations and Delivery: Beyond active pharmaceutical ingredients, patents are filed for novel formulations, delivery systems, and polymorphs of kinase inhibitors to enhance bioavailability, stability, or patient compliance.
Interplay with Patent 8,093,295:
Patent 8,093,295 is part of a larger patent strategy by Bristol-Myers Squibb to protect its kinase inhibitor pipeline. The compounds claimed in this patent likely represent early-stage discovery efforts. Subsequent patents from the same assignee or competitors would typically focus on:
- Specific compounds: Narrower claims for particularly potent or well-characterized analogs.
- Improved properties: Patents covering compounds with enhanced pharmacokinetic profiles, reduced toxicity, or novel mechanisms of action.
- Therapeutic applications: Patents directed to specific indications or patient populations.
- Manufacturing processes: Claims related to the synthesis of these complex molecules.
Competitors seeking to develop similar kinase inhibitors would need to carefully navigate the claims of patent 8,093,295 and any related patents to avoid infringement. This often involves designing around the claimed chemical space or identifying a different, unpatented therapeutic approach.
What is the Prosecution History and Status of Patent 8,093,295?
Understanding the prosecution history provides insight into the scope and limitations of the granted patent. The examination process involves interaction between the applicant (Bristol-Myers Squibb) and the United States Patent and Trademark Office (USPTO) examiner.
Key Aspects of Prosecution:
- Filing Date: The application that led to patent 8,093,295 was filed on March 16, 2009.
- Examination: During examination, the examiner reviewed the application for novelty, non-obviousness, and enablement, comparing it against prior art (existing patents and publications).
- Office Actions: The examiner issued Office Actions detailing rejections or objections to the claims. The applicant responded with arguments and amendments to overcome these rejections.
- Amendments: It is common for applicants to amend claims to narrow their scope, clarify ambiguities, or specifically distinguish them from prior art. For example, substituent definitions might be narrowed, or specific limitations added to method claims.
- Issuance: Upon successful resolution of all rejections and objections, the patent was granted on January 10, 2012.
Status:
As of the current analysis, patent 8,093,295 is granted. However, patents have a limited term. The patent term for applications filed on or after June 8, 1995, is 20 years from the filing date, subject to adjustments.
-
Original Expiration Date Calculation:
- Filing Date: March 16, 2009
- Term: 20 years
- Potential Expiration Date: March 16, 2029
-
Potential for Patent Term Extension (PTE): The patent may have been eligible for Patent Term Extension under 35 U.S.C. ยง 154(b) to compensate for delays during regulatory review (e.g., FDA approval). If PTE was granted, the expiration date would be extended. Without specific information on PTE, the statutory expiration is March 16, 2029.
-
Maintenance Fees: To remain in force, periodic maintenance fees must be paid to the USPTO. Failure to pay these fees can result in the patent lapsing prematurely. It is standard practice for assignees to maintain issued patents with commercial value.
What is the Commercial Significance and Potential for Litigation?
The commercial significance of patent 8,093,295 is tied to the potential of the claimed cyclic urea compounds as therapeutic agents. If any of these compounds or closely related analogs have advanced into clinical development or reached the market, the patent would represent a valuable asset for Bristol-Myers Squibb, potentially generating substantial revenue through sales and preventing generic competition.
Potential for Litigation:
Given the competitive nature of kinase inhibitor development and the broad claims of patent 8,093,295, there is a significant potential for patent litigation.
- Infringement Claims: If a competitor develops and markets a drug that falls within the scope of any of the claims of patent 8,093,295 (particularly the compound claims), Bristol-Myers Squibb could initiate an infringement lawsuit. This would involve proving that the competitor's product directly infringes one or more of the patent's claims.
- Design-Around Strategies: Competitors often attempt to "design around" existing patents by developing compounds that are structurally distinct from the patented claims while achieving a similar therapeutic effect. However, the breadth of the genus claim in patent 8,093,295 may make this challenging.
- Inter Partes Review (IPR): Competitors or other parties might challenge the validity of the patent through an IPR proceeding at the USPTO. This involves arguing that the patent claims are invalid based on prior art that was not considered during the original examination.
- Exclusivity and Market Entry: The patent provides a period of exclusivity, preventing others from making, using, selling, or importing the claimed inventions without authorization. This is crucial for recouping R&D investment and maintaining market share.
The specific commercial products potentially covered or challenged by this patent would depend on the subsequent development and market introduction of compounds fitting Formula (I). Without disclosure of specific Bristol-Myers Squibb drugs derived from this patent, or competitor products that might be accused of infringement, the exact commercial impact and litigation risk remains speculative. However, the nature of the patent and its assignee positions it within a highly scrutinized and litigious area of pharmaceutical R&D.
Key Takeaways
- Compound Genus: Patent 8,093,295 claims a broad class of cyclic urea compounds with potential therapeutic applications.
- Targeted Therapy: The compounds are designed to inhibit protein kinases implicated in diseases such as cancer, inflammation, and autoimmune disorders.
- Broad Claims: The patent's independent claims, particularly the compound genus claim, offer extensive protection within a defined chemical space.
- Active Landscape: The kinase inhibitor field is highly competitive, with numerous players and ongoing patent activity.
- Exclusivity and Risk: The patent provides market exclusivity until its expiration, estimated around March 16, 2029 (subject to PTE), and carries significant potential for patent litigation.
Frequently Asked Questions
-
What is the specific chemical structure of the compounds claimed in Patent 8,093,295?
The patent claims a genus of cyclic urea derivatives defined by Formula (I), with extensive definitions for various substituents (R1-R11 and X) that dictate the specific chemical variations.
-
Does Patent 8,093,295 claim any specific approved drugs?
Patent 8,093,295 claims a genus of compounds and specific exemplified compounds. Whether any specific FDA-approved drugs are encompassed within these claims requires a detailed comparison of the approved drug's structure against the patent's claim limitations. Bristol-Myers Squibb would typically pursue narrower patents for specific marketed drugs.
-
When does Patent 8,093,295 expire?
The patent's statutory expiration date is 20 years from its filing date, which is March 16, 2029. This date could be extended by Patent Term Extension if granted due to regulatory delays.
-
Can other companies develop and sell cyclic urea derivatives while Patent 8,093,295 is in force?
Other companies can develop such compounds if their structures fall outside the scope of the claims in Patent 8,093,295 or if they obtain a license from Bristol-Myers Squibb. Any compound or method that infringes the patent's claims would be prohibited.
-
What is the primary therapeutic mechanism of the compounds claimed in the patent?
The primary therapeutic mechanism is the inhibition of protein kinase activity, which is central to cell signaling pathways involved in various diseases.
Citations
[1] Bristol-Myers Squibb Company. (2012). Cyclic urea derivatives. U.S. Patent No. 8,093,295. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
